InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Enters Binding Terms To Acquire CL-273 For EGFR-Mutant Lung Cancer
March 2, 2026
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, has entered into binding terms to acquire CL-273 from Celyn Therapeutics, Inc., a company backed by OrbiMed and Torrey Pines Investment. CL-273 is an investigational, reversible, wild-type-sparing pan-EGFR small-molecule inhibitor discovered using a proprietary AI-driven drug discovery platform and designed to target resistant mutations in EGFR-mutant non-small cell […]
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Signs Term Sheet to Acquire Two Clinical-Stage NSCLC Assets
February 26, 2026
Kairos Pharma (NYSE American: KAPA) announced it has signed a term sheet for a strategic asset acquisition from Celyn Therapeutics Inc., under which it would obtain worldwide rights to CL-273, a pre-IND, wild-type-sparing pan-EGFR inhibitor, and CL-741, a Phase 1-ready, oral type IIb c-MET kinase inhibitor targeting non-small cell lung cancer. The company said the proposed […]
InvestorNewsBreaks – Kairos Pharma (NYSE American: KAPA) To Participate In DealFlow Discovery Conference
January 20, 2026
Kairos Pharma (NYSE American: KAPA) announced it will participate in the DealFlow Discovery Conference to be held Jan. 28–29, 2026, at the Borgata Hotel, Casino & Spa in Atlantic City, N.J. The company said Chief Scientific Officer Neil Bhowmick will deliver a company presentation and conduct one-on-one meetings with investors during the event as Kairos continues […]
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Receives Clinical Trials Arena Research and Development Award for Advanced Prostate Cancer
December 17, 2025
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on cancer therapeutics, has been named a winner of the 2025 Clinical Trials Arena Excellence Awards, receiving the Research and Development Award for Advanced Prostate Cancer. The recognition highlights the Company’s work advancing ENV-105 (carotuximab), a first-in-class CD105-targeting monoclonal antibody being developed to address treatment resistance […]
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Highlights 2025 Milestones and Clinical Progress in CEO Letter to Shareholders
November 4, 2025
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company developing innovative cancer therapeutics, released a Letter to Shareholders from CEO John Yu, M.D., outlining 2025 accomplishments and the outlook for 2026. The Company reported positive interim safety and efficacy results from its Phase 2 trial of ENV105 in combination with apalutamide for advanced metastatic prostate cancer, […]
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Reports Positive Interim Phase 2 Results for ENV-105 in Advanced Prostate Cancer
October 20, 2025
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company developing innovative cancer therapeutics, announced positive interim efficacy data from its ongoing Phase 2 trial of ENV-105 (carotuximab) in men with metastatic castration-resistant prostate cancer. Presented at the European Society for Medical Oncology meeting in Berlin, the study showed clinical benefit in 86% of patients treated with […]
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Reports Positive Interim Phase 2 Data for ENV105 in Prostate Cancer
September 18, 2025
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company developing cancer therapeutics, announced positive interim efficacy data from its ongoing Phase 2 trial of ENV105 (carotuximab) in metastatic castration-resistant prostate cancer. Among eight evaluable patients, the ENV105 and apalutamide combination achieved median progression-free survival of more than 13 months, with five patients still on treatment and […]
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) to Host KOL Event on Phase 2 ENV105 Prostate Cancer Trial
September 11, 2025
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company developing innovative cancer therapeutics, announced it will host a key opinion leader event on Sept. 18, 2025, at 5 p.m. ET to discuss interim efficacy results from its Phase 2 trial of lead candidate ENV105 in advanced prostate cancer. CEO Dr. John Yu said the event will […]
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) to Present at H.C. Wainwright Global Investment Conference
September 4, 2025
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announced that CEO and Chairman John Yu, MD, will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference, being held Sept. 8–10, 2025, at the Lotte New York Palace Hotel in New York. To view the full […]
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) to Present Initial Phase 1 Data of ENV105 at World Lung Cancer Conference
September 3, 2025
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, announced participation and presentation of initial Phase 1 data of ENV105 in non-small cell lung cancer by Principal Investigator Dr. Karen Reckamp at the World Lung Cancer Conference, taking place Sept. 6–9, 2025, at the Fira de Barcelona Gran Via in Barcelona, […]
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) to Present at H.C. Wainwright Global Investment Conference
July 16, 2025
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharma company advancing cancer therapeutics, will participate in the H.C. Wainwright 27th Annual Global Investment Conference, scheduled for September 8–10, 2025, at the Lotte New York Palace Hotel in New York City. The company will host one-on-one meetings and deliver a presentation available virtually via kairospharma.com. To view the […]
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Reports Positive Safety Results in Phase 2 Study of Prostate Cancer Drug ENV-105
July 15, 2025
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharma company developing cancer therapies, announced favorable interim safety results from its ongoing Phase 2 trial of ENV-105 (carotuximab) in patients with metastatic castration-resistant prostate cancer. The first-in-class CD105 antagonist showed no dose-limiting toxicities or unexpected adverse events in the first ten patients, and no Grade 3 or 4 […]
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Highlights Positive Preclinical Data for KROS101 at ASCO 2025
June 3, 2025
Kairos Pharma (NYSE American: KAPA) presented new preclinical data at the ASCO 2025 Annual Meeting on its investigational small molecule GITR ligand agonist, KROS101. The study, titled “Effect of KROS 101, a small molecule GITR ligand agonist, on T effector cells, T reg cells and intratumoral CD8 T cell cytotoxicity,” demonstrated KROS101’s dual mechanism of enhancing […]
InvestorkNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) to Participate in D. Boral Capital Global Conference on May 14
May 6, 2025
Kairos Pharma (NYSE American: KAPA) announced it will participate in the D. Boral Capital Inaugural Global Conference on May 14, 2025, at The Plaza Hotel in New York City. CEO and Chairman John Yu, MD, will host one-on-one meetings with investors from 9 a.m. to 3 p.m. ET. To view the full press release, visit https://ibn.fm/ieEAZ […]
InvestorkNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) to Present KROS 101 Data at 2025 ASCO Annual Meeting
April 28, 2025
Kairos Pharma (NYSE American: KAPA), announced it will present new data on KROS 101, a small molecule GITR ligand agonist, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The poster, titled “Effect of KROS 101, a small molecule GITR ligand agonist, on T effector cells, T reg cells and intratumoral CD8 T cell […]
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Secures DoD Grant to Advance Lung Cancer Biomarker Research
April 24, 2025
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company, issued a shareholder letter from CEO John Yu, M.D., outlining recent progress and strategic developments. The company is advancing two clinical trials for lead candidate ENV105 in prostate and EGFR-dependent non-small cell lung cancers, with safety and interim efficacy results expected in Q2 2025. Kairos is also […]
InvestorkNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Secures DoD Grant to Advance Lung Cancer Biomarker Research
April 17, 2025
Kairos Pharma (NYSE American: KAPA) announced that the U.S. Department of Defense has awarded $876,000 to Cedars-Sinai Medical Center to support biomarker research for Kairos’ Phase 1 trial of ENV105 in EGFR-driven non-small cell lung cancer. The study focuses on patients developing resistance to osimertinib, aiming to identify those who may benefit from early intervention with […]
InvestorkNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Completes Safety Lead-In for Phase 2 Prostate Cancer Trial
March 31, 2025
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced completion of the safety lead-in for its Phase 2 trial evaluating ENV105 in combination with apalutamide for metastatic, castration-resistant prostate cancer. The trial will now proceed with patient randomization to assess apalutamide alone versus the combination therapy. Safety and efficacy data from the lead-in phase are […]
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Gains Traction with Conference Participation and Analyst Coverage
March 28, 2025
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company, reported recent activity at major scientific gatherings and announced upcoming conference appearances. The company presented research on its GITR agonist KROS 101 at the Society for Immunotherapy of Cancer Spring Meeting on March 12, participated in BIO Europe from March 17 to 19, and will attend the […]
InvestorkNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Publishes Findings on Overcoming NSCLC Drug Resistance
March 20, 2025
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company, has published a peer-reviewed study highlighting a potential breakthrough in addressing drug resistance to EGFR-targeted therapies for non-small cell lung cancer (NSCLC). The study, published in Drug Resistance Updates, identifies CD105 (endoglin) as a key factor in mediating resistance to osimertinib, a frontline treatment for EGFR-mutant NSCLC. […]
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Presents Positive Preclinical Data on KROS 101 and KROS 401 at AACR IO Conference
February 26, 2025
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company, presented preclinical data on its investigational compounds KROS 101 and KROS 401 at the American Association for Cancer Research Immuno-Oncology (AACR IO) conference held in Los Angeles from Feb. 23-26, 2025. The data highlighted KROS 101’s ability to inhibit tumor growth and boost T cell responses in […]
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Secures $600K in Funding for ENV205 Development
February 18, 2025
Kairos Pharma (NYSE American: KAPA) announced that Cedars-Sinai Medical Center, through its academic partnership with the company, has received $600,000 from the Department of Defense Lung Cancer Research Program to support the development of ENV205. This first-in-class therapy aims to counteract chemotherapy drug resistance and cachexia, a severe muscle-wasting condition affecting cancer patients. The funding will […]
InvestorkNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Adds Huntsman Cancer Institute to Phase 2 Trial for Prostate Cancer Therapy
February 11, 2025
Kairos Pharma (NYSE American: KAPA) has added Huntsman Cancer Institute in Salt Lake City as a site for its Phase 2 clinical trial of ENV105 for castrate-resistant prostate cancer. The trial, supported by the National Cancer Institute, evaluates ENV105 in combination with apalutamide. Chief Scientific Officer Dr. Neil Bhowmick emphasized Huntsman’s role in expanding patient access […]
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Highlights Preclinical Data on GITR Agonist KROS 101 at AACR-JCA Conference
February 6, 2025
Kairos Pharma (NYSE American: KAPA) presented preclinical data on its GITR agonist, KROS 101, during the plenary session of the AACR-JCA conference. The study demonstrated that KROS 101 enhances T cell infiltration, proliferation, and tumor-killing ability in melanoma and glioblastoma models while reducing regulatory T-cell suppression. Compared to the GITR antibody TRX518, KROS 101 showed superior […]
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) to Present at AACR-JCA Joint Conference on Innovative Cancer Therapy
January 28, 2025
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced it will present during the plenary session of the 13th AACR-JCA Joint Conference, “From Cancer Discovery Science to Therapeutic Innovation,” taking place Feb. 1-5, 2025, in Maui, Hawaii. The presentation, titled “KROS 101: A Next-Generation GITR Agonist Boosting Anti-Tumor T Cell Responses and Reprogramming the Tumor […]
InvestorkNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Highlights 2024 Milestones and 2025 Clinical Outlook
January 21, 2025
Kairos Pharma (NYSE American: KAPA) reflected on its 2024 progress and outlined key 2025 milestones in a letter to shareholders. Last year’s achievements included its initial public offering, collaborations with PreCheck Health Services and City of Hope Cancer Center, and advancements in clinical trials for ENV105 targeting prostate and lung cancers. Notable developments also included the […]
InvestorkNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) to Present at Lytham Partners Investor Healthcare Summit
January 7, 2025
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced that CEO John S. Yu, M.D., and Chief Scientific Officer Neil Bhowmick will present a corporate overview at the Lytham Partners Investor Healthcare Summit on Jan. 13, 2025. The conference will be held virtually. To view the full press release, visit https://ibn.fm/hMLee About Kairos Pharma Ltd. Based […]
InvestorNewsBreaks – EF Hutton Provided ‘Buy’ Rating, $9.00 Price Target in Kairos Pharma, Ltd. (NYSE: KAPA) Recent Research Report
December 20, 2024
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on advancing innovative oncology therapeutics, was featured in an EF Hutton report that initiated coverage with a buy rating and a price target of $9.00 per share. EF Hutton, which recently rebranded to D. Boral Capital LLC, is an investment bank dedicated to providing exceptional […]
InvestorNewsBreaks – Kairos Pharma, Ltd. (NYSE: KAPA) Receives ‘Buy’ Recommendation, $12.00 Price Target in Rodman & Renshaw Research Report
December 18, 2024
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on advancing innovative oncology therapeutics, is spotlighted today in a Rodman & Renshaw, LLC report that initiated coverage with a buy rating and a price target of $12.00 per share. Based in New York City, Rodman & Renshaw is a full-service investment bank with a […]
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) to Present Growth Strategy at The Microcap Conference 2025
December 16, 2024
Kairos Pharma (NYSE American: KAPA) has announced its participation in The Microcap Conference 2025, set for January 28-30 at the Borgata Hotel Spa & Casino in Atlantic City, NJ. The company’s management team will present recent developments, growth strategies, and investment opportunities, while engaging in one-on-one meetings with investors. The Microcap Conference, the largest independent microcap […]
InvestorkNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Expands Phase 2 Trial of ENV105 to City of Hope for Prostate Cancer Therapy
December 3, 2024
Kairos Pharma (NYSE American: KAPA) announced the inclusion of City of Hope Cancer Center in California in its Phase 2 clinical trial for ENV105, targeting castrate-resistant prostate cancer. The trial, supported by Kairos Pharma and a National Cancer Institute grant, evaluates ENV105’s potential to overcome hormone therapy resistance in combination with apalutamide. Adding City of Hope […]
InvestorkNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Engages IBN for Corporate Communications Expertise
November 26, 2024
Kairos Pharma (NYSE American: KAPA) is a clinical-stage biopharmaceutical company focused on advancing innovative oncology therapeutics. The company’s development pipeline targets drug resistance and immune suppression, two critical barriers to effective cancer treatment. With a robust pipeline, experienced leadership, as well as an intellectual property portfolio extending to 2040, Kairos Pharma is uniquely positioned to […]
IBN Initiates Coverage of Kairos Pharma Ltd.
November 26, 2024
LOS ANGELES, Nov. 26, 2024 (GLOBE NEWSWIRE) — via IBN – Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on advancing innovative oncology therapeutics, has selected IBN, a multifaceted financial news and publishing company for private and public entities, to spearhead its corporate communications efforts. Kairos Pharma’s development pipeline targets drug resistance and immune suppression, two […]
Kairos Pharma Ltd. (NYSE: KAPA) Developing Innovative Therapies to Tackle Cancer Drug Resistance, Immune Suppression
November 25, 2024
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company, is dedicated to advancing innovative oncology therapies to overcome critical challenges in cancer drug resistance and immune suppression, two significant challenges to effective cancer treatment. With an extensive intellectual property portfolio valid until 2035 to 2040, the company is developing a notable pipeline of drugs tackling […]
InvestorNewsBreaks – Kairos Pharma Ltd. (KAPA) to Dual List Shares on Upstream, Expanding Global Investor Access
November 19, 2024
Kairos Pharma (KAPA) announced its approval for a dual listing on Upstream, a MERJ Exchange market and global securities trading app, with trading set to begin on November 26 under the ticker symbol ‘KAPA.’ The listing aims to broaden Kairos Pharma’s investor base beyond the U.S., enhance liquidity, and facilitate price discovery. Investors can prepare […]
Kairos Pharma Ltd. (NYSE American: KAPA) Is ‘One to Watch’
November 12, 2024
Kairos Pharma (NYSE American: KAPA) is a clinical-stage biopharmaceutical company focused on advancing innovative oncology therapeutics that target drug resistance and immune suppression, two significant barriers in effective cancer treatment. By addressing these mechanisms, Kairos aims to restore the efficacy of standard cancer treatments while enhancing the body’s natural immune responses against tumors. The company’s […]
InvestorNewsBreaks – 5th Annual Blockchain Futurist Conference Revolutionizes Ticketing with Crypto Integration Powered by EukaPay
August 11, 2023
The 5th Annual Blockchain Futurist Conference is set to take place on August 15-16 in Toronto, organized by Untraceable Events. Regarded as Canada’s premier crypto, web3, and blockchain gathering, the event is poised to draw over 6,500 attendees and feature 150+ speakers. What sets this conference apart is its integration of cryptocurrency into ticket purchases […]
The 5th Annual Blockchain Futurist Conference to Support Crypto Ticketing Powered by EukaPay
May 24, 2023
Canada’s largest and most high-profile crypto, web3, and blockchain event returns to Toronto from August 15-16, 2023. Promising a crypto experience like no other and opportunities to learn about emerging technologies that could disrupt industries, the event weaves hands-on technology into every aspect, enabling participants to engage with each other and the technologies around which […]
Blockchain Futurist Conference Continues To Grow with ETHToronto Hackathon as part of Canada’s Largest Blockchain Event
May 18, 2022
Witness a futuristic immersive experience at Blockchain Futurist Conference, Canada’s largest cryptocurrency and blockchain event being held from August 9-10th, 2022 at Rebel Entertainment Complex & Cabana, Toronto, Canada. This larger-than-life event will be held inside the 45,000 sq foot social playground and includes access to the outdoor cabana area of the spectacular waterfront venue. […]
InvestorNewsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) Adds Key Personnel to Support Growth
May 17, 2022
Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has released a list of new employees that have been carefully hired to fuel the company’s success and support the company’s growing EV offerings, including the Mullen FIVE EV Crossover and Mullen ONE EV Cargo Van. The individuals are filling roles in an array of […]